Evidence map›Paper›PMID 21142023›Full record

ReviewMolecular pharmaceutics2011

Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents.

Jacqueline N Parker, Xiaojia Zheng, William Luckett, James M Markert, Kevin A Cassady

Abstract readReview
In one paragraph

Review in Molecular pharmaceutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Current status of gene therapy for brain tumors.Translational research : the journal of laboratory and clinical medicine · 2013
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jacqueline N ParkerDepartment of Pediatrics, Cell Biology and Anatomy, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. jnparker@uab.edu
Xiaojia Zheng
William Luckett
James M Markert
Kevin A Cassady

Funding

Virus Production CoreP01CA071933 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROIZMAN, BERNARD · 1997 to 2013
$14.5M
Viral and molecular chemotherapy of malignant CNS tumorsP50CA097247 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GILLESPIE, G. YANCEY · 2002 to 2009
$13.5M
ENGINEERED HERPES SIMPLEX VIRUS FOR TREATMENT OF GLIOMASK08NS001942 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MARKERT, JAMES M · 1997 to 2001
$245k
NCI NIH HHS 5P50CA97247NCI NIH HHS P01 CA071933NCI NIH HHS P01 CA71933NCI NIH HHS P50 CA097247NINDS NIH HHS 1K08NS01942NINDS NIH HHS K08 NS001942
6 · The paper itself

Abstract

Conditionally replication-competent Herpes Simplex Virus Type 1 (HSV-1) vectors expressing foreign genes have been developed as experimental therapeutic agents. Traditional methods of virus construction, including growth selection based on thymidine kinase gene expression, and color selection based on a reporter gene expression are often time-consuming and relatively inefficient. This review summarizes the various strategies developed in recent years for the rapid and efficient construction of novel conditionally replication-competent mutant HSV expressing multiple foreign genes. Additionally, two new modifications of existing strategies, which have not been previously reported, are discussed.

Indexed as

Genetic TherapyGenetic VectorsHerpesvirus 1, HumanHumansNeoplasmsVirus Replication

Identifiers

PMID21142023
PMCPMC3034828

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.